Ivax wins round in Pacitaxel patent battle, is likely to remain. (Markets: Life Sciences).(paving the way for continued sales of a generic version of Bristol-Myers Squibb Co.)(Brief Article)

Chemical Market Reporter, January, 2002 by Krause, Carey

IN A GENERICS battle in the $1 billion US branded paclitaxel market, Ivax Corp. has won a key patent lawsuit in a federal district court in California, paving the way for continued sales of the company's generic version of Bristol-Myers Squibb Company's (BMS) anticancer drug Taxol. Paclitaxel sales account for about 15 percent of Ivax's total sales.

The district court granted summary judgment invalidating American BioSciences Inc.'s (ABI) paclitaxel patent claims against Ivax. Analysts say the possibility of removal of Ivax's Onxol (paclitaxel) from the market, even temporarily, is remote. This action comes in the wake of a federal appeals court decision in Washington, D.C., also last week, which denied Ivax's motion for reconsideration of a ruling in...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.